DIA

Latin America Annual Meeting

SEPTEMBER 9-11, 2026 | Mexico City, Mexico

CALL FOR ABSTRACTS

ABSTRACT SUBMISSION DETAILS AND GUIDELINES
SUBMISSION DEADLINE: February 18, 2026

Are you a professional involved in the regulatory/clinical and safety and pharmacovigilance functional areas within a company or organization working on pharmaceuticals, medical devices, and/or diagnostics in Latin America? If so, DIA wants to hear from you!

The Latin America Annual Meeting continues to evolve to meet the needs of organizations to advance and implement life sciences R&D initiatives in Latin America and the Caribbean. Our tracks on Regulatory/Clinical and Safety and Pharmacovigilance expand the scope of the meeting, with cross-track sessions and workshops facilitating discussions on key connection points across these areas to promote collaboration and synergy within organizations.
Let your voice help shape the future of Life Science Innovation in the region. Submit your abstract today!

To ensure that we have the most comprehensive and cutting-edge program, we are seeking abstract submissions from professionals like yourself, who are pushing the boundaries in their respective fields. We encourage you to submit abstracts that reflect the latest trends, innovations, and best practices in regulatory, clinical, and pharmacovigilance in Latin America. We will be accepting the following formats:

- **Presentations:** 15-20-minute presentation to be bundled with other presentations to create a session (1 author/speaker)
- **Sessions:** 60-75-minute total session (1 author/speaker + 2 additional speakers)
- **Workshop:** 60-75-minute workshop delivered in an interactive/simulation or role-playing format (1 author/speaker + 2 additional speakers)
- **Short Courses**: three-hour interactive workshop delivered in a small group format. These will be delivered virtually and require a separate fee from attendees. (3 speakers maximum, must all be from different companies)

The Latin America Annual Meeting Program Committee is seeking abstracts on the following topics (keep in mind, business use cases and lessons learned are encouraged in all topic areas). Please note that this meeting is attended by many regulatory professionals, service providers, and health authority representatives, and therefore, topics in addition to those listed below that you feel are relevant may be submitted for evaluation and possible selection.

Regulatory/Clinical Track

The regulatory/clinical track offers a dynamic platform to explore the evolving regulatory landscape and clinical research practices across Latin America. Participants will engage with real-world case studies, best practices, and emerging trends across life science R&D. This track showcases innovative approaches that strengthen regulatory functions and institutional performance, while supporting effective compliance, regional and multi-regional cooperation, and practical strategies for the successful development, approval, and lifecycle management of both pharmaceutical products and medical devices.

Regulatory:

- Current Challenges, Opportunities, and Best Practices in Achieving Efficient Regulatory Oversight in the LATAM Region
- Advances in Artificial Intelligence (AI) and Technology
- Good Reliance Practices (e.g., optimizing regional reliance initiatives)
- Facilitating Access to Innovation in LATAM (e.g., practical pragmatic approaches).
- Regulatory Priorities, Plans, Projects, and Updates from Regional and National Regulatory Authorities
- eCTD, Cloud-Based Submissions, and data structuring for marketing authorization
- Advanced Therapy Medicinal Products (ATMPs)
- Effect of Emerging Regulations on Global Registration Strategies
- Orphan Drugs and Rare Diseases
- Good Regulatory Practices
- ICH Updates
- Emergency Preparedness
- Good Manufacturing Practices and Regulatory Inspections (in-person and virtual)
- Regulatory Intelligence and Regulatory Strategy
- Regulatory considerations for Medical Devices and Wearables in the LATAM Region
- Regulatory Collaboration and Cooperation Initiatives (e.g., cross-industry collaborations, regulatory joint initiatives)
- Health Technology Assessments (HTA)
- Utilization of Real-World Data (RWD) and Real-World Evidence (RWE) for Regulatory Decision Making
- Regulatory Convergence (e.g., implementation of ICH guidelines, International Medical Device Regulators Forum [IMDRF])
- Tools for Strengthening Regulatory Systems in the Americas (e.g. WHO Global Benchmarking Tool [GBT], and WHO Listed Authority [WLA] designation)
- Lifecycle management, and Chemistry, Manufacturing and Controls (CMC)
- Digital Health Landscape (e.g., e-Labeling, software as a medical device [SaMD], global IDMP, applicable regulatory frameworks, and other digital solutions).
- Counterfeiting, smuggling, and substandard quality medical products

Clinical:

- Use of AI and Technology in Clinical Trials
- Good Clinical Practice (e.g., ICH E6 (R3) revision)
- Utilization of RWD and RWE in Clinical Trials
- Multiregional Clinical Trials
- Innovative Clinical Trial Designs and Development Approaches

Submit Your Abstract at DIAglobal.org/Abstracts

CALL FOR PRESENTATION ABSTRACTS

SUBMISSION DEADLINE: February 18

Clinical (continued):

- Clinical Trials Submissions and Approvals
- Clinical Trial Data Collection, Management, and Sharing
- Clinical Trial Operational Challenges, Best Practices, and Lessons Learned from Sponsors
- Life Cycle Management (e.g., post-approval changes)
- Clinical Evaluation and Trial Requirements for Medical Devices
- Decentralized Clinical Trials (DCTs)
- Patient Engagement and Centricity
- Clinical Endpoints (e.g., surrogate endpoints)
- Quality and Compliance in Clinical Operations
- Representation in Clinical Trials
- Outsourcing Clinical Operations (e.g., hybrid)
- Clinical Trial Disclosure and Data Transparency
- Participant Recruitment and Retention Best Practices and Lessons Learned
- Statistical Considerations for Clinical Trial Design
- Clinical Research Sites and Trial Execution Excellence

Safety and Pharmacovigilance Track

Dive into the latest advancements in clinical safety and pharmacovigilance for pharmaceutical products and medical devices within the dynamic landscape of Latin America. Our safety and pharmacovigilance track offers attendees a deep dive into essential topics, including best practices, case studies, and regulatory compliance strategies, ensuring a comprehensive understanding of this critical aspect of the life sciences industry.

- Current Challenges, Opportunities, and Best Practices in Strengthening Pharmacovigilance in the LATAM Region (regional challenges and current landscape).
- Use of Artificial Intelligence (AI), Machine Learning (ML), Automation, and Technology in Pharmacovigilance (e.g., Zero touch case processing, automated causality assessment algorithm)
- ICH Safety Related Updates
- Risk Management Tools and Techniques
- Training and Education in Pharmacovigilance
- Post-approval Safety Studies and use of RWD and RWE data.
- Regulatory Challenges for Pharmacovigilance Operational Processes and Procedures
- Risk Communication and Advances in Patient Safety (e.g., digital healthcare systems (Industries / Health Care Institutions / Academia), medication alerts, facilitating information sharing, etc.)
- Technovigilance
- Best Practices for Safety Governance Models
- Vaccines safety activities (PV activities for vaccines and the integrated process with National Immunization Programs – experiences in Latam)
- Post-Market Surveillance of Medical Devices (e.g., class II, class III)
- Pharmacovigilance for Novel Therapies, such as Advanced Therapies / Pharmacogenomics
- Advanced Techniques in Signal Detection
- GVP Inspections (in-person and virtual)
- Pharmacovigilance Activities Related to Clinical Trials
- Crisis Management and Preparing for Future Pandemics

GENERAL SUBMISSION REQUIREMENTS

- All submissions must be submitted online
- For complete submission requirements and to submit your abstract go to DIAglobal.org/Abstracts

SUBMISSION TIPS

- Ideal submissions will contain practical content and shared experiences
- Theoretical topics and content is acceptable, however, it should be supported with proof of concepts and use cases
- Diverse topics and sessions are welcomed and encouraged within the scope of the forum
- Please select the interest area that best fits with your proposal. If your topic is relevant to more than one interest area, please indicate that in your abstract summary.
- Abstracts should be written using clear language and descriptions to provide enough clarity for the selection committee to review and understand

REQUIRED DOCUMENTATION FOR ALL ABSTRACTS

- Participant Disclosure Information: All abstract authors must disclose any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he or she must complete and submit a Participant Disclosure in order to participate in the program.

- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted abstracts will be available on DIA's website for attendee download.

CALL FOR PRESENTATION ABSTRACTS

SUBMISSION DEADLINE: February 18

SUBMISSION GUIDELINES

Submitting a PRESENTATION ABSTRACT (All abstracts must be submitted online)

15-20-minute presentation, bundled with other presentations to create a session. Abstract author is considered the presenter (co-presenters are not permitted) and will be responsible for:

- Adhering to the program development guidelines and timelines
- Working with chair and other presenters in creating a balanced program offering
- Preparing and delivering a PowerPoint presentation

Submitting a SESSION ABSTRACT (All abstracts must be submitted online)

60-75-minute total session. Abstract author will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting speakers and ensuring good representation/diversity in their selection. Maximum of 3 speakers per session (including author) and 1 speaker per company
- Working with the Session Chair to communicate with speakers regarding their role in the session

Submitting a WORKSHOP ABSTRACT (All abstracts must be submitted online)

60-75-minute total workshop. Abstract author will be responsible for:

- Adhering to the program development guidelines and timelines.
- Recruiting co-instructors and ensuring good representation/diversity in their selection. (3 speakers maximum, must all be from different companies).
- Ensuring the workshop provides onsite learning in the form of activities or demonstrations.
- Working with the Session Chair to communicate with speakers regarding their role in the session.

Submitting a SHORT COURSE ABSTRACT (All abstracts must be submitted online)

Three-hour, interactive presentation delivered in small group format. Abstract author is considered the Short Course Lead Instructor and will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting co-instructors and ensuring good representation/diversity in their selection. (3 speaker max, must all be from different companies)
- Communicating with co-instructors regarding their role in the short course and reviewing presentation materials (note: PowerPoint presentations are required from each instructor)
- Managing the short course, including the facilitation of audience questions and interactions

Abstract Submission Deadline: February 18, 2026

Notification: Week of May 8, 2026

Final PowerPoint Presentations Due: August 19, 2026

Please submit all abstracts online at: DIAglobal.org/Abstracts

Questions: Contact Lynda Fisher, Senior Project Manager, Specialty Meetings at Lynda.Fisher@DIAGlobal.org

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Author Information

Abstract Information

Track: Select Regulatory/Clinical or Safety and Pharmacovigilance

Interest Area: Choose from the drop down

Keywords: Provide one or more keywords to highlight your abstract.

Examples of keywords: Personalized Medicine, Health Technology Assessment, etc. (100 characters)

Level of Difficulty: Beginner, Intermediate, or Advanced

Learning Objectives: Provide 2-3 learning objectives that clearly explain what participants should be able to do after attending this event. For a list of suggested verbs to create these objectives, click here. (400 Characters)

Overview: Please provide 2-3 sentences summarizing your abstract. This summary will be used as the overview description in the DIA program for marketing purposes (250 Characters including spaces)

Abstract Details: Please provide complete details about your abstract. Information such as scientific, technical, process issues, design/methods, results/outcomes, case studies, statistics, key findings, etc., that would support your proposal should be included here. This information will be used by the Program Committee to learn more about the purpose of your abstract. Is there an interactive component to your topic? If so, please indicate in the abstract details how you would be able to include an interactive learning experience for attendees. (2000 Characters including spaces)